Keywords : COVID-19

Similarities and differences of COVID-19 and avian infectious bronchitis from molecular pathologist and poultry specialist view point

Waseem Al-Jameel; Saevan Saad Al-Mahmood

Iraqi Journal of Veterinary Sciences, 2020, Volume 34, Issue 2, Pages 223-231
DOI: 10.33899/ijvs.2020.126984.1426

Coronaviruses (CoVs) are important RNA viruses that affect respiratory, gastrointestinal and urinary system of human being and birds. These viruses originated from the subfamily Coronavirinae which genetically includes Alphacoronavirus, Beta coronavirus, Gamma coronavirus and Delta coronavirus. The sequencing analysis of the genome showed that COVID-19 caused by SARS-CoV-2 belongs to Beta coronavirus genus and avian infectious bronchitis caused by IBV comes from Gamma coronavirus genus. Over the past few decades and until now, the world showed that endemic outbreaks of infectious bronchitis in avian caused by IBV. Once more, the world sees the emergence of another new human coronavirus COVID-19 outbreak due to a new strain called SARS-CoV-2. Whole genetic material and comparative genomic analysis exhibited that IBV and SARS-CoV-2 have particularly same genomic structures and characteristics. Both have a spike protein in the genome structure which allows that SARS-CoV-2 attaches to their human select cells throughout ACE2 receptors, that are notably reported in the lung and kidney. While IBV uses alpha (2,3) linked sialic acids-dependent manner for bind to the avian tissues which is notably reported in the lung and kidney. The two diseases are produced a pulmonary and urinary infection that lead to sneezing, gasping, respiratory massive destruction, severe pneumonia and renal failure. This review will introduce a general overview of two diseases and describe the phylogeny, epidemiology, pathogenesis, clinical features, autopsy report and microscopic lesions.

Are promising mechanisms of hydroxychloroquine abolish COVID-19 activity? A review study

Yaareb J Mousa; Mahmood B. Mahmood; Fanar A. Isihaq; Ammar A. Mohammed

Iraqi Journal of Veterinary Sciences, 2020, Volume 34, Issue 2, Pages 345-349
DOI: 10.33899/ijvs.2020.127049.1449

To explore the benefits of Hydroxychloroquine (HCQ), (which is an antimalarial agent that has shown effective pharmacological properties in different malarial conditions and immunological disorders, particularity in chloroquine-sensitive malaria), in the treatment and prevention of Corona Virus Disease-2019 (COVID-19) pandemic because HCQ was recently advocated to minimize the pathogenicity of COVID-19. The aim of this review is to shed the light on a possible mechanism by which HCQ can defeat the COVID-19, a disease characterized by the WHO as a pandemic. Literatures from Web of Science, Scopus, PubMed, Science Direct and Google Scholar were cast-off to search the literature data. The keywords used are antimalarial agent, COVID-19, Hydroxychloroquine, SARS-CoV-2 and Zinc sulfate.The review summarizes the benefits of using HCQ against COVID-19 through exploiting the ability of this antimalarial agent in ameliorating the body immunity, inhibiting and/or delaying the viral glycosylation by increasing the pH inside the host cell and also via suppressing the viral transcription and replication through the formation of a complex structure after binding with zinc. We concluded thatthese interfering properties of HCQ support human immunity to fight against the progression of COVID-19. We hypothesize that the therapeutic efficiency of HCQ against the COVID-19 can be enhanced by the concurrent administration of zinc sulfate.